Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Research Domains
  1. Home
  3. Research Domains

Related Concept Videos

  • Biomedical And Clinical Sciences
  • Oncology And Carcinogenesis
  • Predictive And Prognostic Markers
  • Elevated Pretreatment Lactate Dehydrogenase And Albumin-to-alkaline Phosphatase Ratio Predict Poor Prognosis And Early Treatment Discontinuation In Head And Neck Cancer Patients With Preexistent Diabetes Mellitus.
  • Biomedical And Clinical Sciences
  • Oncology And Carcinogenesis
  • Predictive And Prognostic Markers
  • Elevated Pretreatment Lactate Dehydrogenase And Albumin-to-alkaline Phosphatase Ratio Predict Poor Prognosis And Early Treatment Discontinuation In Head And Neck Cancer Patients With Preexistent Diabetes Mellitus.

    • Related Experiment Video

    Assessment of the Metabolic Profile of Primary Leukemia Cells
    06:21

    Assessment of the Metabolic Profile of Primary Leukemia Cells

    Published on: November 21, 2018

    10.5K

    Elevated pretreatment lactate dehydrogenase and albumin-to-alkaline phosphatase ratio predict poor prognosis and early treatment discontinuation in head and neck cancer patients with preexistent diabetes mellitus.

    Camil Ciprian Mireștean, Mihai Cosmin Stan, Roxana Irina Iancu

      Bratislavske Lekarske Listy
      |June 29, 2024

      View abstract on PubMed

      Summary
      This summary is machine-generated.

      Serum lactate dehydrogenase (LDH) and albumin-to-alkaline phosphatase ratio (AAPR) show prognostic value in head and neck cancer patients with diabetes mellitus. These biomarkers can predict treatment response and survival outcomes in HNC patients with DM.

      More Related Videos

      Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line
      06:24

      Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line

      Published on: April 11, 2025

      277
      Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
      07:39

      Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

      Published on: June 6, 2025

      73

      Related Experiment Videos

      Assessment of the Metabolic Profile of Primary Leukemia Cells
      06:21

      Assessment of the Metabolic Profile of Primary Leukemia Cells

      Published on: November 21, 2018

      10.5K
      Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line
      06:24

      Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line

      Published on: April 11, 2025

      277
      Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
      07:39

      Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

      Published on: June 6, 2025

      73

      Area of Science:

      • Oncology
      • Metabolic Medicine
      • Biomarker Research

      Background:

      • Increased serum lactate dehydrogenase (LDH) indicates cellular necrosis and is a marker in head and neck squamous cell carcinoma (HNSCC).
      • Albumin-to-alkaline phosphatase ratio (AAPR) is a cost-effective biomarker associated with longer survival in solid tumors.
      • Diabetes mellitus (DM) negatively impacts HNSCC outcomes, but metformin may offer benefits by inhibiting tumor metabolism.

      Purpose of the Study:

      • To evaluate the prognostic value of pretreatment serum LDH and AAPR in predicting treatment duration and glycemic control in head and neck cancer (HNC) patients with DM.
      • To assess the utility of LDH and AAPR as predictive biomarkers in HNC patients co-existing with diabetes mellitus.

      Main Methods:

      • Retrospective analysis of pretreatment serum LDH and AAPR levels in HNC patients with DM.
      • Inclusion of data from oncology clinic and outpatient departments of Craiova County Hospital.
      • Exploration of the correlation between biomarkers, treatment response, and glycemic control.

      Main Results:

      • Both LDH and AAPR demonstrate potential as pre-treatment biomarkers for predicting treatment response in HNC patients with DM.
      • These biomarkers can be incorporated into multi-parametric models for prognostic assessment in HNC associated with DM.
      • Glycemic control significantly impacts LDH levels, necessitating assessment and control of DM before evaluating these biomarkers.

      Conclusions:

      • LDH and AAPR are valuable predictive and prognostic biomarkers for HNC patients with DM.
      • A recommended cut-off value of 0.5 for these biomarkers should be considered after assessing DM status.
      • Multicentric trials with larger patient cohorts are required to validate these findings.